Tome Biosciences
Latest round
- Series B
Last raised
- Dec 2023
Total raised
- $213M
Investors
- 7
About Tome Biosciences
Based in the US and founded in 2021, Tome Biosciences, Inc. is a biotechnology firm that is developing programmable gene insertion technology. The company was co-founded by Omar Abudayyeh and Jonathan Gootenberg. In December 2023, Tome Biosciences Inc. The company offers technologies that allow any genetic sequence of any size to be injected into any genome at any location using CRISPR. The firm is working on genomic therapeutics, delivering cures to patients through cell and genome engineering. The startup develops a variant of CRISPR that can insert 36,000 base pairs into the genome at once. Tome Biosciences, Inc.
Who invested in Tome Biosciences
7 investors across 2 rounds
See all investors in Tome Biosciences
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Tome Biosciences
Who invested in Tome Biosciences?
Tome Biosciences has 7 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Tome Biosciences raised?
Tome Biosciences has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Tome Biosciences last raise money?
Tome Biosciences's most recent round on record is a Series B, in Dec 2023.
What does Tome Biosciences do?
Based in the US and founded in 2021, Tome Biosciences, Inc.
Where is Tome Biosciences headquartered?
Tome Biosciences is headquartered in Watertown, US.
Which VCs invest in companies like Tome Biosciences?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Tome Biosciences's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Tome Biosciences? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.